Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:08:11 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - http://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q0.1881.22·890.450.1883.20-7.48-0.8505.6444,93316,238881.72  887.4794  875.225998.325  684.80516:54:51Apr 2515 min RT 2¢

Recent Trades - Last 10 of 16238
Time ETExPriceChangeVolume
16:54:51Q883.20-7.481,136
16:36:44Q881.21-9.472
16:28:55Q883.20-7.4899
16:25:37Q882.49-8.191
16:19:43Q883.20-7.481
16:19:33Q882.7584-7.9216726
16:16:01Q883.20-7.48516
16:15:03Q883.20-7.481
16:07:40Q883.20-7.481
16:06:39Q883.20-7.4824

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 07:00U:REGNNews ReleaseRegeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
2024-04-24 10:05U:REGNNews ReleaseRegeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
2024-04-22 17:54U:REGNNews ReleaseRegeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
2024-04-07 16:00U:REGNNews ReleaseLinvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
2024-04-01 16:05U:REGNNews ReleaseRegeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
2024-03-25 07:00U:REGNNews ReleaseRegeneron Provides Update on Biologics License Application for Odronextamab
2024-03-12 23:55U:REGNNews ReleaseHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
2024-03-11 07:00U:REGNNews ReleasePraluent(TM) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
2024-03-08 07:00U:REGNNews ReleaseEYLEA(TM) HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
2024-02-23 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
2024-02-21 07:00U:REGNNews ReleaseLinvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
2024-02-16 00:59U:REGNNews ReleaseJapan First in the World to Approve Dupixent ‚ ® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
2024-02-06 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2024-02-02 06:30U:REGNNews ReleaseRegeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2024-02-02 06:00U:REGNNews ReleaseLinvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
2024-01-30 07:01U:REGNNews ReleaseRegeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
2024-01-25 14:29U:REGNNews ReleaseDupixent ‚ ® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
2024-01-24 12:05U:REGNNews ReleaseTop 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards